The sequencing decision most researchers get wrong
These three compounds are not interchangeable options for the same goal. The confusion starts at the mechanism level, and the timing rule nobody accounts for is the one that determines whether a GH peptide produces a result at all.
For educational and research purposes only. This is not medical advice and is not human-use guidance. Consult a qualified professional before acting on anything here.
Start here
What each compound is actually doing
Most sequencing confusion starts here. People treat these three compounds as interchangeable options for the same goal. They are not. Each one operates on a different mechanism and solves a different problem.
Retatrutide
Triple receptor — GLP-1, GIP, and glucagonTargets three receptors: GLP-1, GIP, and glucagon. The GLP-1 component reduces how much you eat. The GIP component improves how efficiently the body processes fat. The glucagon receptor, the one no other GLP-1 compound has, tells the body to burn stored energy, not just eat less. That third receptor is what makes retatrutide behave differently than older GLP-1 compounds. It moves the scale from the outside.
The job: operates on intake, fat processing efficiency, and energy expenditure through three separate receptor pathways at once.
Tesamorelin
GHRH analog — growth hormone releasing hormoneA stabilized analog of GHRH, the signal the brain sends to the pituitary to produce a GH pulse. It does not introduce external growth hormone. It uses and amplifies the body's own natural pulse. The target is visceral fat, the fat stored around the organs on the inside. Based on the data, tesamorelin also carries a lean mass preservation effect during caloric restriction, which is part of why it earns its place alongside a GLP-1 compound.
The job: reshapes what is underneath. Operates on visceral fat reduction and lean mass signaling through the body's own GH pulse mechanism.
CJC-1295 (no DAC)
GHRH analog — same receptor as tesamorelinAlso a GHRH analog, the same receptor as tesamorelin and the same upstream mechanism. DAC refers to Drug Affinity Complex, an attachment that extends half-life. The version without it keeps the release pattern closer to a natural pulse shape. It loads the pituitary to produce growth hormone and is designed to be paired with a GHRP like ipamorelin, which fires the pulse. Running both CJC-1295 and tesamorelin at the same time does not add signal, because both activate the same receptor pathway, which makes simultaneous use redundant rather than additive.
The job: an alternative route to GH support. Not a companion to tesamorelin, since the decision is always one GHRH compound per protocol.
Where these compounds overlap, and where they don't
Retatrutide and tesamorelin do not cancel each other out. They do not compete at the receptor level. One is a GLP-1 class compound, the other is a GH secretagogue: different pathways, different mechanisms, different problems solved.
Tesamorelin and CJC-1295 do overlap. Both activate GHRHR, the growth hormone releasing hormone receptor, which makes simultaneous use redundant rather than additive. Running both does not produce a stronger signal. It produces the same signal twice. The decision is always one GHRH compound per protocol.
Retatrutide strips the weight. Tesamorelin reshapes what is underneath. CJC-1295 is the alternative route to that GH support layer, not a companion to it.
Free — no payment required
Read the timing and sequencing framework
The timing rule that changes when a GLP-1 is active, how to choose between tesamorelin and CJC-1295, and the readiness checklist for the full stack. One email opens this guide and every other free research guide on the site.
No spam. Used only for research guide access and occasional protocol updates from Project Theo.
Part two
The timing problem nobody talks about
This is where most researchers running retatrutide lose the benefit of their GH peptide. The problem is not the compound. The problem is the window.
Retatrutide slows gastric emptying continuously, not just around injection time. This is a property of the GLP-1 mechanism. The consequence is that a genuinely fasted state is harder to confirm than it was before the GLP-1 was introduced. Both tesamorelin and CJC-1295 require a fasted state to produce a clean GH pulse. When insulin is elevated, even from a partially filled stomach, the pituitary receives the signal but the downstream release is blunted. The compound is not failing. The window is wrong.
The compound is not failing. The window is wrong.
Find your timing window
Is a GLP-1 compound active in your current protocol?
Which GH peptide are you using?
Timing reference
| Variable | What research suggests |
|---|---|
| Standard GH peptide fast — no GLP-1 active | 2 hours from last meal is the generally used research window before injecting tesamorelin or CJC-1295. |
| GH peptide fast with retatrutide active | Research on the GLP-1 mechanism and its continuous effect on gastric emptying suggests extending to at least 3 hours. The standard 2-hour window becomes unreliable when a GLP-1 is active. |
| Best timing window | Fasted morning injection before any food intake. This is the most reliable window for both tesamorelin and CJC-1295 when a GLP-1 is active in the protocol. |
| CJC-1295 with ipamorelin — injection sequence | Inject CJC-1295 first. Wait 15 to 30 minutes. Then inject ipamorelin. This sequence remains the same regardless of what else is in the stack. |
| Tesamorelin with ipamorelin | Standard pairing. Tesamorelin loads the pituitary. Ipamorelin fires the pulse. Always paired at each injection window. |
Part three
Choosing between tesamorelin and CJC-1295
Both are valid research pathways. The choice depends on the specific problem being addressed and where the protocol currently stands.
tesamorelin
CJC-1295
How to read the protocol phase signal. The bottom row is a prerequisite check, not a tally signal. Selecting the option showing body fat is still elevated produces a separate read, because neither compound is the right call at that phase. The GLP-1 handles this phase on its own. The framework above applies once weight is managed and visceral fat is the specific remaining target.
Part four
The stack that actually makes sense
Retatrutide plus tesamorelin plus ipamorelin is a legitimate research framework when the timing is right. The question is not whether these compounds can be combined. The question is whether the protocol has earned the stack.
Adding tesamorelin when body fat is still elevated adds complexity that retatrutide handles on its own. The goal is always to identify the actual bottleneck before adding a compound to address it.
Retatrutide first. Establish it. Let the weight move. Then evaluate whether a GH support layer has a specific problem to solve.
Research frameworks suggest this layer becomes relevant when lean mass is sliding or visceral fat is the remaining target, not as a hypothetical but as a documented observation in the current protocol. Protein intake needs to be adequate, training quality needs to be there, and sleep is not a variable to set aside. A GH peptide layered on top of a compromised foundation does not fix the foundation.
Check the conditions before the compound
The items below reflect the conditions under which the stack has a specific problem to solve. Check the ones that currently apply. The read updates as you go and saves to this device, so you can return to it as the protocol develops.
This returns a read on the conditions around the stack decision. It does not return a compound, a dose, or a protocol, because those depend on variables that are not visible from here.
Nothing checked yet. Work through the list above and a read will appear here.
The original guide as a PDF
The page is the current version. The PDF is the takeaway if you want it offline.
Download the PDFNext step
Find the bottleneck before you add the compound
The whole argument of this guide is confirming the actual limit before layering on another compound. The Protocol Bottleneck Tool maps your exact situation across seven bottleneck categories and shows where the friction most likely is. Free, no login, takes about three minutes. If you would rather read first, the guide catalog holds every free research guide on the site.